| Popis: |
Management of antithrombotic agents at the time of endoscopy involves a balancing act between the risk of thromboembolic events from interruption of treatment and that of procedure-related bleeding events from continuation of treatment. In general, patients who undergo procedures with low bleeding risk can continue their antithrombotic medications, regardless of the risk for thromboembolism. Patients at low risk for thromboembolism who undergo procedures with higher bleeding risk can temporarily discontinue antithrombotic medications and be maintained in the subtherapeutic range in the periprocedural period. Patients at moderate-to-high risk for thromboembolic events who are undergoing procedures with high bleeding risk are a challenge to manage. Providers must be familiar with the bleeding risks of particular procedures, identify those at highest risk for thromboembolism, recognize when bridging therapy is indicated, and know when to interrupt and reinitiate antithrombotic therapy. |
